HCV Treatment
EASL 2013: Second-generation Protease Inhibitor Faldaprevir Cures up to 80% of Genotype 1 Hepatitis C
- Details
- Category: HCV Treatment
- Published on Monday, 29 April 2013 00:00
- Written by Keith Alcorn
A second-generation HCV protease inhibitor, faldaprevir (formerly BI 201335), cured up to 80% of previously untreated people with genotype 1 hepatitis C virus infection when combined with pegylated interferon and ribavirin, Peter Ferenci of the Medical University of Vienna reported on Saturday at the EASL International Liver Congress (EASL 2013) in Amsterdam. A response gap was observed, however, between HCV subtypes 1a and 1b.
EASL 2013: Daclatasvir + Sofosbuvir Offers Rescue Therapy after Current Standard of Care
- Details
- Category: HCV Treatment
- Published on Sunday, 28 April 2013 00:00
- Written by Liz Highleyman
An interferon-free regimen of daclatasvir plus sofosbuvir, with or without ribavirin, cured all previously treated hepatitis C patients who did not respond to interferon-based triple therapy using the approved HCV protease inhibitors boceprevir (Victrelis) or telaprevir (Incivek), according to a report presented at the EASL International Liver Congress (EASL 2013) this week in Amsterdam.
EASL 2013: MK-5172 Boosts Interferon/Ribavirin Response Regardless of IL28B Status
- Details
- Category: HCV Treatment
- Published on Saturday, 27 April 2013 00:00
- Written by Liz Highleyman
The experimental HCV protease inhibitor MK-5172 increased sustained response rates to over 90% when added to pegylated interferon/ribavirin in a study of previously untreated genotype 1 hepatitis C patients, researchers reported this week at the EASL International Liver Congress (EASL 2013) this week in Amsterdam.
Coverage of the 2013 EASL International Liver Congress
- Details
- Category: HBV Treatment
- Published on Saturday, 27 April 2013 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013) in Amsterdam, April 24-28, 2013.
Conference highlights include treatment for hepatitis B and C, new direct-acting HCV drugs, interferon-free hepatitis C therapy, management of liver disease complications, and prevention and treatment of hepatocellular carcinoma.
4/27/13
EASL 2013: Sofosbuvir + Ribavirin Cures Most Genotype 2 Hepatitis C, but Genotype 3 Response Is Lower
- Details
- Category: HCV Treatment
- Published on Friday, 26 April 2013 00:00
- Written by Liz Highleyman
A dual oral regimen containing the hepatitis C polymerase inhibitor sofosbuvir plus ribavirin produced high sustained virological rates overall, but this was driven by very good response among people with HCV genotype 2, while those with genotype 3 did not fare as well, researchers reported this week at the 48th EASL International Liver Congress (EASL 2013) in Amsterdam.
More Articles...
- EASL 2013: AbbVie Interferon-free Combination Cures Over 90% of Hepatitis C Genotype 1
- EASL 2013: International Liver Congress Kicks Off with Hep C New Drug Highlights
- Janssen Submits Approval Requests for New Hepatitis C Drug Simeprevir
- Daclatasvir + Asunaprevir Works Well for Patients Who Cannot Use Interferon
Web Design and Development by